It is now clearly established that both the metabolic activity and the molecular structure of the gut microbiota control the development of metabolic and cardiovascular diseases. All along the gastrointestinal tract, from the mouth to the anus, bacteria that colonize the corresponding epithelia metabolize not only nutrients but also food components that are not absorbable by humans, along with cell residues and byproducts.
In addition, they synthesize new molecules from those produced by the host, such as secondary bile acids. Therefore, molecular constituents such as lipopolysaccharides, peptidoglycans and flagellin, metabolic products, especially those generated by fermentation, such as short-chain fatty acids, nitrosylated and sulphonated molecules, derivatives of eukaryotic cells (deconjugated bile acid), and serotonin-derived intestinal hormones, constitute a means of communication between the host and the microbiota.
Can a chemical entity aimed at a microbiota-specific intestinal target serve as a therapeutic solution in cardiometabolic diseases?

Pr. Rémy Burcelin
Pr. Rémy Burcelin
Publication type
Download the publication